Oxaliplatin Eugia (Uk) (Oxaliplatin)

Oxaliplatin is used primarily for colorectal cancer treatment, often as part of combination chemotherapy protocols.

• Metastatic colorectal cancer: enhances survival when combined with fluorouracil and leucovorin.
• Adjuvant therapy for stage III colon or rectal cancer: reduces recurrence risk after surgical resection.
• Advanced gastrointestinal tumours: used off‑label in clinical trials for gastric and pancreatic cancers.

• Oxaliplatin forms reactive platinum‑DNA adducts that disrupt DNA replication and transcription, leading to cell‑cycle arrest and apoptosis in rapidly dividing tumour cells. Its activity is distinct from other platinum agents due to the diaminocyclohexane carrier ligand, which enhances cytotoxicity in colorectal tumour lines.

Oxaliplatin may elicit a range of adverse reactions, most of which are dose‑dependent and reversible.

Common Side Effects

• Peripheral neuropathy: tingling or numbness, often worsening with cumulative dose.
• Nausea and vomiting: may require anti‑emetic prophylaxis.
• Diarrhoea: usually mild to moderate.
• Fatigue: generalized tiredness during treatment cycles.
• Thrombocytopenia: reduced platelet count observed in blood tests.

Serious or Rare Side Effects

• Severe peripheral neuropathy: persistent sensory loss that may be irreversible.
• Acute allergic‑type reactions: flushing, shortness of breath, or hypotension during infusion.
• Hematologic toxicity: neutropenia or severe anemia requiring medical intervention.
• Hepatotoxicity: elevated liver enzymes indicating liver stress.
• Cardiac arrhythmias: uncommon but reported during rapid infusions.

• When handling Oxaliplatin, clinicians ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​ ​  ​     ​  ​  ​  ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ...
• -  
• t  
• t 
• d ... ... ... ... ... ... ............ ... ...  ... ... ... ... ... ... ... ... ... ... ... ......